{"slug":"sino-biopharm","name":"중국생물제약(시노바이오팜)","name_en":"Sino Biopharm","ticker":"1177.HK","updated_at":"2026-07-11T10:21:34.417+00:00","canonical":"https://valuechain.wiki/sino-biopharm","kicker":"항셍 지수","kicker_en":"Hang Seng Index","lead":"중국 대형 제약사로 간질환, 항암, 심혈관 분야의 처방의약품을 개발·판매하는 기업이다. 항셍 지수 구성종목. 밸류체인 관계·수치 데이터는 조사 전인 기본 노드로, AI 질문 수요가 관측되면 상세 노드로 승격된다.","lead_en":"A large Chinese pharmaceutical company developing prescription drugs in hepatology, oncology, and cardiovascular care. Hang Seng Index constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.","segments":{"parts":[{"name":"항종양"},{"name":"간질환"},{"name":"심혈관·호흡기"}],"total":"약 ¥262억 (FY2023)"},"segments_en":{"parts":[{"name":"Oncology"},{"name":"Liver disease"},{"name":"Cardio-cerebral & respiratory"}],"total":"approx. CN¥26.2B (FY2023)"},"returns_yearly":{"2021":-25,"2022":-13.5,"2023":-36.8,"2024":2.4,"2025":138.7,"2026":-20.9},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":null,"analysis_en":null,"analysis_asof":null},"edges":[]}